Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Advancis launches new strength Keflex capsules
“With the availability of Keflex 750mg capsules, physicians and other healthcare professionals will be able to deliver a total daily dose of Keflex with fewer capsules per day,”
“With the availability of Keflex 750mg capsules, physicians and other healthcare professionals will be able to deliver a total daily dose of Keflex with fewer capsules per day,”
The grant was submitted in response to President George W Bush’s executive order encouraging innovation in manufacturing and provides funding of approximately $1.2 million over a two-year period.
Galapagos was awarded the grant through the Institute for the Promotion of Innovation by Science and Technology (IWT). As part of this program, Galapagos will collaborate with three
The randomized, double blind, placebo-controlled studies are intended to assess the efficacy and safety of pre-seasonal treatment with PreHistin on moderate to moderately severe seasonal ragweed allergy patients.
The collaboration, which will involve biological research aimed at understanding inflammatory signaling pathways, will initially last for a period of one and a half years. Shanghai Genomics, an
This effort includes the development of guidances to provide greater clarity and transparency in the disclosure of waivers of relationships that could present the appearance of conflicts of
In a paper published online in the Proceedings of the National Academy of Sciences (PNAS), a team from the National Institutes for Health (NIH) Chemical Genomics Center demonstrated
Encysive received another approvable letter for Thelin (sitaxsentan sodium), which is under review for the treatment of pulmonary arterial hypertension (PAH), in March. Investors had hoped that, this
Elaprase (idursulfase) is the first and only treatment approved for people suffering from Hunter syndrome, a rare, life-threatening genetic condition also known as mucopolysaccharidosis II. The product, which
After having successfully completed phase II clinical trials, Altus had previously planned to initiate phase III trials for both ALTU-135 and ALTU-238 in the second half of this